Full Name
DR Shahjahan Shaid
Speaker Bio
Dr. Shahjahan Shaid currently leads the team of Novel Analytical Technologies within the Global MSAT organization of GSK aimed at enabling the company strategy to introduce new analytical technologies which covers reduction of animal testing and animal derived materials by substituting them with state-of-the-art technologies.
Shahjahan joined Novartis Vaccines, now GSK, in 2013 to lead and implement innovative technologies in the Quality Control of the company. Prior to that, he worked for diagnostics of zoonoses at the German Federal Health Robert Koch Institute.
Shahjahan holds a PhD in Biology with a focus on immunology and host pathogen interaction and has experience in the pharmaceutical vaccine industry with an extensive knowledge of introducing novel assays in cGMP.
Shahjahan joined Novartis Vaccines, now GSK, in 2013 to lead and implement innovative technologies in the Quality Control of the company. Prior to that, he worked for diagnostics of zoonoses at the German Federal Health Robert Koch Institute.
Shahjahan holds a PhD in Biology with a focus on immunology and host pathogen interaction and has experience in the pharmaceutical vaccine industry with an extensive knowledge of introducing novel assays in cGMP.
